
THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 463 Session of
2001

INTRODUCED BY GEORGE, THOMAS, DeWEESE, CAPPABIANCA, YOUNGBLOOD,
McILHATTAN, READSHAW, BELARDI, ROBINSON, WOJNAROSKI,
M. COHEN, CRUZ, CAWLEY, COSTA, LAUGHLIN, SURRA, TIGUE,
T. STEVENSON, MELIO, TRELLO, ROONEY, KENNEY, SOLOBAY,
SAINATO, WALKO, HENNESSEY, DERMODY, STABACK, L. I. COHEN,
LEDERER, BELFANTI, HORSEY, SHANER, KAISER, COY, HERSHEY AND
DeLUCA, FEBRUARY 5, 2001

REFERRED TO COMMITTEE ON HEALTH AND HUMAN SERVICES,
FEBRUARY 5, 2001

AN ACT

1 Authorizing a grant program for Type 1 diabetics; providing for
2 powers and duties of the Department of Health; and making an
3 appropriation.

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. Short title.

7 This act shall be known and may be cited as the Juvenile
8 Diabetes Research Grant Act.

9 Section 2. Definitions.

10 The following words and phrases when used in this act shall
11 have the meanings given to them in this section unless the
12 context clearly indicates otherwise:

13 "Department." The Department of Health of the Commonwealth.

14 "Master Settlement Agreement." The settlement agreement and
15 related documents entered into on November 23, 1998, by the

1 Commonwealth and leading United States tobacco product
2 manufacturers and approved by the court in Commonwealth v.
3 Philip Morris, April Term 1997, No.2443 (C.P. Philadelphia
4 County), on January 13, 1999.

5 "Secretary." The Secretary of Health of the Commonwealth.

6 "Type 1 diabetic." A person from birth to 18 years of age
7 who has been diagnosed with Type 1 diabetes.

8 "Type 1 diabetes research facility." A facility located
9 within this Commonwealth, with an existing program conducting
10 research of Type 1 diabetes and integrally related areas
11 affecting persons with Type 1 diabetes, as well as the
12 development of immunology and transplantation.

13 Section 3. Payment for Type 1 diabetes research.

14 (a) Grants authorized.--The department shall provide grants
15 for research on Type 1 diabetes.

16 (b) Distribution of funding.--

17 (1) The secretary, in cooperation with the Physician
18 General, shall administer and distribute each annual
19 appropriation as grants to Type 1 diabetes research
20 facilities.

21 (2) The grant funds under this act shall be paid to the
22 research facility only if the funds are used to supplement
23 and not supplant existing funding from the Board of Regents
24 for the Diabetes Institute for Immunology and
25 Transplantation.

26 (c) Terms and conditions.--Each grant approved by the
27 department under this act shall contain the following terms and
28 conditions:

29 (1) The facility shall use the funds for research
30 relating to islet cell transplantation, islet cell

1 distribution and related areas affecting Type 1 diabetics.

2 (2) The facility shall use advanced technology to
3 enhance the longevity and the quality of the lives of Type 1
4 diabetics.

5 (d) Amount of grants.--The amount of each grant awarded
6 under this act shall be determined by the secretary.

7 (e) Regulations.--The department shall promulgate rules,
8 regulations and standards for the award of the grants authorized
9 by this act.

10 Section 4. Reporting.

11 Each grant recipient shall annually report to the secretary
12 and to the Health and Human Services Committee of the Senate and
13 the Health and Human Services Committee of the House of
14 Representatives on its use of funds received under this act and
15 the progress made in research on islet cell transplantation,
16 islet cell distribution and related areas. In reporting on its
17 use of the funds, the annual report must include, but is not
18 limited to, the amount of money the institute received from the
19 academic health center, the specific purposes for which the
20 funds were spent and verification that the funds were spent for
21 allowable purposes according to this section. In reporting on
22 progress made in research on transplantation, distribution and
23 related areas, the annual report must include, but is not
24 limited to:

25 (1) Data generated from the transplants on the benefits
26 and disadvantages of islet cell transplantation, including
27 data on the restoration and maintenance of tight blood sugar
28 control and insulin independence following transplantation.

29 (2) Data on health care dollars per quality adjusted
30 life-year saved.

1 (3) Progress on achievement of health insurance coverage
2 for islet cell transplantation procedures.

3 Section 5. Appropriation.

4 The sum equal to 2% of the moneys received by the
5 Commonwealth from the Master Settlement Agreement is hereby
6 appropriated to the Department of Health from the moneys for the
7 fiscal year July 1, 2001, to June 30, 2002, for the purpose of
8 awarding grants to Type 1 diabetes research in accordance with
9 this act. This appropriation shall be a continuing appropriation
10 and shall not lapse at the end of the fiscal year.

11 Section 6. Effective date.

12 This act shall take effect in 60 days.